A new way to reduce inflammation after a stroke
A New Anti-inflammatory Therapy for Ischemic Stroke
['FUNDING_OTHER'] · CORNOVUS PHARMACEUTICALS, INC. · NIH-11192329
This research is developing a new drug to help reduce inflammation in the brain after an ischemic stroke, aiming to improve recovery for patients.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CORNOVUS PHARMACEUTICALS, INC. (nih funded) |
| Locations | 1 site (NEW HAVEN, UNITED STATES) |
| Trial ID | NIH-11192329 on ClinicalTrials.gov |
What this research studies
Current treatments for ischemic stroke are limited, and many patients still face high rates of death or disability. This project focuses on a new approach to help the brain heal by blocking inflammation caused by immune cells. Researchers have found a promising drug candidate that has shown positive effects in animal models of stroke and can block specific inflammatory cells from healthy human subjects. The goal is to conduct necessary safety and manufacturing studies to prepare this drug for potential testing in people.
Who could benefit from this research
Good fit: This early-stage research is not yet recruiting patients, but future studies would likely focus on individuals who have recently experienced an ischemic stroke.
Not a fit: Patients with other types of stroke or those without active inflammation may not directly benefit from this specific anti-inflammatory approach.
Why it matters
Potential benefit: If successful, this new anti-inflammatory drug could lead to improved outcomes and better recovery for patients who have experienced an ischemic stroke.
How similar studies have performed: While the specific drug candidate is novel, the concept of targeting inflammation after stroke is an active area of research with ongoing investigations into various anti-inflammatory strategies.
Where this research is happening
NEW HAVEN, UNITED STATES
- CORNOVUS PHARMACEUTICALS, INC. — NEW HAVEN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LIANG, BRUCE T — CORNOVUS PHARMACEUTICALS, INC.
- Study coordinator: LIANG, BRUCE T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.